MOG antibody-associated disease (MOG-AD, sometimes written MOGAD) is an autoimmune condition in which the immune system makes an antibody against myelin oligodendrocyte glycoprotein (MOG) — a protein on the surface of the myelin that insulates nerves in the brain, optic nerves and spinal cord. It is a distinct disease from both multiple sclerosis (MS) and NMOSD, even though it can look like either of them at first.
There is genuine good news in the MOG-AD story: many people have a single episode and recover well, and even when the condition relapses it usually responds to treatment. The key is an accurate diagnosis using the right antibody test, interpreted carefully.
What is MOG-AD?
The MOG antibody triggers inflammation and loss of myelin (demyelination). Unlike MS, MOG-AD often allows good recovery between episodes; and unlike AQP4-positive NMOSD, it targets myelin rather than astrocytes. It affects children and adults, and men and women roughly equally.
How MOG-AD can present
👁️ Optic neuritis
Often in both eyes, sometimes recurrent, with pain and vision loss. Visual recovery is frequently good.
🦴 Transverse myelitis
Spinal cord inflammation with weakness, numbness and bladder symptoms.
🧠 ADEM (acute disseminated encephalomyelitis)
Particularly in children: widespread brain inflammation with drowsiness, confusion and multiple symptoms.
⚡ Brain and brainstem inflammation
Including a seizure-associated form sometimes called FLAMES.
How MOG-AD is diagnosed
🔬 MOG-IgG antibody test
A blood test using a cell-based assay. The strength of the result matters: a clearly positive (high-titre) test in the right clinical setting supports the diagnosis, while a low-positive result must be interpreted with caution, because it can occur without true disease.
🧪 AQP4 antibody test
To exclude NMOSD.
🧲 MRI
MRI (magnetic resonance imaging) of the brain, optic nerves and spinal cord.
💧 Lumbar puncture
Oligoclonal bands are usually absent (unlike MS), which is a helpful clue.
Why testing technique matters: MOG and AQP4 antibodies must be measured with modern cell-based assays, and low-level results need expert interpretation. Relying on a weak positive can lead to an incorrect diagnosis — one reason subspecialty review is valuable.
Treatment of MOG-AD
Acute episodes
Attacks are treated with high-dose intravenous corticosteroids, followed by a gradual oral steroid taper. For severe or steroid-resistant attacks, plasma exchange (PLEX) or intravenous immunoglobulin (IVIG) is used.
Preventing relapses
Not everyone needs long-term treatment — many people have only a single episode. When the disease relapses, preventive options include:
💉 Regular IVIG
Among the better-supported options in MOG-AD.
🧬 Rituximab
B-cell depletion.
💊 Mycophenolate mofetil or azathioprine
Steroid-sparing immunosuppressants used for ongoing prevention.
⏳ Slow corticosteroid tapers
In the early phase.
Importantly, MOG-AD does not respond to some treatments used in AQP4-positive NMOSD — the complement inhibitor eculizumab, for example, is not effective in MOG-AD. This is another reason the two conditions must be told apart.
Reassuring: most people with MOG-AD recover well from episodes — especially their vision — and treatment is effective at controlling the disease if it does relapse.
Outlook
The outlook for MOG-AD is generally more favourable than for AQP4-positive NMOSD, particularly for those who have a single episode. Ongoing monitoring helps decide whether, and for how long, preventive treatment is needed.
MOG-AD care at East Neurology
Dr Tal Koren provides subspecialty neuroimmunology care for MOG-AD at East Neurology in Bondi Junction — careful antibody interpretation, MRI review, acute treatment, and a clear plan on whether preventive therapy is needed. He works alongside Dr Ron Granot and the wider team.
Frequently asked questions
Is MOG-AD a type of MS?
No — it is a separate disease with its own antibody and, often, better recovery between episodes. Telling them apart changes treatment.
Will I need lifelong treatment?
Not necessarily. Many people have a single episode. Long-term preventive treatment is usually reserved for those who relapse.
My MOG test was “weakly positive” — what does that mean?
Low-level MOG results can occur without true MOG-AD. The result must be interpreted alongside your symptoms and MRI; subspecialty review helps avoid over-diagnosis.
Related reading
- Neuroimmunology — overview of conditions and team
- NMOSD — neuromyelitis optica spectrum disorder
- Multiple sclerosis
- Dr Tal Koren — Consultant Neurologist (Neuroimmunology)
External resources
- MS Australia — information and support
This page is general information about MOG antibody disease and is not personal medical advice. Please contact the practice to discuss your individual situation.
Book an appointment
To arrange a consultation about MOG-AD with Dr Tal Koren, ask your GP or specialist for a referral, then get in touch — new patients and second opinions are welcome.
Or call 02 9388 0615. East Neurology is a private specialist practice focused on expert diagnosis and prompt results; your Medicare rebate is processed for you on the day.